Advanced Filters
noise

Taipei County, Taiwan Clinical Trials

A listing of Taipei County, Taiwan clinical trials actively recruiting patients volunteers.

Found 981 clinical trials

Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy

According to health authorities guidances (FDA 2006, EMA(European Medicines Agency) 2009) for gene therapy clinical trials, observing subjects for delayed adverse events for 15 years is recommended. This purpose of this long-term follow-up study is to evaluate the safety and efficacy in patients who have ever received lentiviral-based gene-edited immune …

years of age All Phase N/A
H Hu-Ming Chang

Trans-cranial Direct Current Stimulation on Alcohol Craving

The goal of thisclinical trial is to investigate the efficacy of trans cranial direct current stimulation (tDCS) for alcohol craving in individuals with alcohol dependence. The main question it aims to answer is whether 10 sessions of tDCS can reduce craving for alcohol. Participants will be randomized into active group …

20 - 65 years of age All Phase N/A
C Charles Jia-Yin Hou

Biomarkers and Cardiac Imaging Diagnostic Assay for Monitoring Patients With Fabry Disease

Fabry disease (FD) is a rare X-linked lysosomal storage disorder caused by deficient activity of the enzyme α-Gal A resulting from mutations affecting the GLA gene. It is characterized by severe multi-systemic involvement that leads to major organ failure and premature death in affected men and in some women. The …

18 years of age All Phase N/A

Safety of AM-928 Infusion in Advanced Solid Tumors

This is a Phase I, open-label, dose-escalation study for a novel cancer treatment, AM-928, intravenous infusion antibody for advanced solid tumor. The study is aimed to learn the safety, tolerability, pharmacokinetics, and preliminary efficacy profile of AM-928. The dose escalation strategy will adopt accelerated titration combined with a Bayesian optimal …

18 years of age All Phase 1
M Mei-Chen Huang, master

lncRNAs as a Biomarker to Assess the Therapeutic Impact of Oral Absorbent ± Probiotics in CKD Patients With PAD

Participants with chronic kidney disease (CKD) are at a higher risk of developing atherosclerotic peripheral artery disease (PAD). Retention of uremic toxins such as indoxyl sulfate (IS), p-cresyl sulfate (PCS) and trimethylamine N-oxide (TMAO) during CKD is detrimental to endothelial and vascular function and can predispose to the development and …

20 years of age All Phase N/A
K Keh-chung Lin, Sc.D

Proximal Priority Versus Distal Priority Robotic Priming Effects in Patients With Chronic Stroke

This is a single-blind randomized comparative efficacy study involving 54-72 participants with chronic stroke. Participants will be randomized into proximal priority robotic group or distal priority robotic group and receive 18 intervention sessions (90 min/d, 3 d/wk for 6 weeks). The Fugl-Meyer Assessment Upper Extremity subscale, Medical Research Council Scale, …

20 - 75 years of age All Phase N/A
Y Yun Hsiang Lee, Phd

The Effects of Multi-Psycho-Oncology Care Courses

When the patient's mood has not yet reached a moderate to high severity level, psychological support is usually provided by the clinical nurses. However, the result of past research showed that the needs of patients and their caregivers were not satisfied with the psychological level. Scholars pointed out that it …

20 years of age All Phase N/A
C Chih-Hao Chen, MD, PhD

Taiwan Associated Genetic and Nongenetic Small Vessel Disease

The TAG-SVD enrolled patients with clinical and neuroimaging features of cerebral small vessel disease (CSVD). All enrolled patients will receive next-generation sequence (NGS) with probes designed to target five candidate CSVD genes, and patients will be divided into genetic or non-genetic groups accordingly. Their clinical features and outcome will be …

18 years of age All Phase N/A
M Min Shen Dai, MD/PhD

Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients

Objectives: To determine the safety, tolerability, and efficacy of allogeneic PB103 in patients with IIIb/IV or refractory non-small-cell lung cancer

20 - 70 years of age All Phase 1/2
h hsinan hou

Ropeginterferon Alfa 2b for Early MyelofibrosisDIPSS Low/Intermediate-1 Risk Myelofibrosis

This is a multi-centre phase 2 open-label prospective study designed to assess the efficacy and safety of ropeg patients with pre-fibrotic primary myelofibrosis or DIPSS low/intermediate-1 risk myelofibrosis after 24 months of treatment.

20 years of age All Phase 2

Simplify language using AI